Emendo Biotherapeutics Overview
Emendo Biotherapeutics develops next-generation gene-editing tools for genetic disorders, addressing technological gaps for realizing the promise of gene therapy. Emendo genome-editing technology can repair and eliminate genetic mutations in living cells that cause serious diseases or disorders. Emendo's gene-editing solutions are recombination based, highly specific, and have zero off-target effect.
Cumulative Funding Raised Over Time ($)
Latest News
growth-negative
AnGes laying off 110 EmendoBio employees three years after $250 million acquisition | CTech
Japanese pharmaceutical company AnGes is laying off 110 employees at Israeli gene editing technology firm EmendoBio, which it acquired for $250 million in 2020. The future of EmendoBios technology is uncertain. AnGes, which is listed on the Tokyo stock exchange, has seen a significant drop in its share price in recent years. Despite this, it had previously stated it would continue to support EmendoBios operations in Israel and the US. EmendoBio, founded in 2015, uses protein engineering for precision gene editing to treat certain genetic disorders and diseases.
LayoffsAcquisition
growth-negative
אמזון מפטרת גם בישראל; מיקרוסופט בסבב קיצוצים נרחב
Japanese pharma company AnGes is closing down EmendoBio, a genetic editing company it acquired three years ago. EmendoBio, based in Rehovot, currently employs about 110 people in Israel and a few in New York in the fields of molecular biology and bioinformatics. The employees were notified of the closure at the beginning of the week and are now undergoing hearings. The Israeli management of the company refused to comment on the news.
Layoffs
Emendo Biotherapeutics' next generation CRISPR gene editing technologies achieve breakthrough results with allele-specific approach for ELANE-related Severe Congenital Neutropenia as presented at ASGCT Annual Meeting
Emendo Biotherapeutics and Seattle Children's Research Institute Announce Collaboration to Develop CRISPR-based Therapeutic Strategy for Severe Congenital Neutropenia
Emendo Biotherapeutics to Present New Data at 63rd ASH Annual Meeting & Exhibition
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $73M |
| Last funding | $61M |
| Stage | Acquired |
| Rounds | 2 |
| Investors | 2 |
Team Members
3
Employees: 11-50
Web & Social Links
| Website | www.emendobio.com/ |
Locations
Ilan Ramon Street 2, Ness Ziona, Israel
400 W 61st St, New York, NY, USA
Photos & Videos
1 item(s)
